MX2014011104A - Moduladores del receptor x del higado. - Google Patents
Moduladores del receptor x del higado.Info
- Publication number
- MX2014011104A MX2014011104A MX2014011104A MX2014011104A MX2014011104A MX 2014011104 A MX2014011104 A MX 2014011104A MX 2014011104 A MX2014011104 A MX 2014011104A MX 2014011104 A MX2014011104 A MX 2014011104A MX 2014011104 A MX2014011104 A MX 2014011104A
- Authority
- MX
- Mexico
- Prior art keywords
- liver
- compounds
- modulators
- reception
- reception modulators
- Prior art date
Links
- 210000004185 liver Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004311 liver X receptors Human genes 0.000 abstract 2
- 108090000865 liver X receptors Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
Abstract
Se proveen aquí compuestos novedosos y sales farmacéuticamente aceptables de los mismos que son moduladores del receptor X del hígado; también se proveen composiciones que comprenden los compuestos de la invención y un vehículo; adicionalmente se describe el uso de estos compuestos y métodos de tratamiento de una enfermedad o trastorno asociado con el receptor X del hígado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261612063P | 2012-03-16 | 2012-03-16 | |
PCT/US2013/031250 WO2013138568A1 (en) | 2012-03-16 | 2013-03-14 | Liver x reception modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014011104A true MX2014011104A (es) | 2014-12-05 |
MX354820B MX354820B (es) | 2018-03-21 |
Family
ID=47997958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014011104A MX354820B (es) | 2012-03-16 | 2013-03-14 | Moduladores del receptor x del higado. |
Country Status (28)
Country | Link |
---|---|
US (5) | US9073931B2 (es) |
EP (1) | EP2825542B1 (es) |
JP (3) | JP6114815B2 (es) |
KR (1) | KR102069913B1 (es) |
CN (1) | CN104203950B (es) |
AU (1) | AU2013232069B2 (es) |
BR (1) | BR112014022780A8 (es) |
CA (1) | CA2865639C (es) |
CY (1) | CY1118323T1 (es) |
DK (1) | DK2825542T3 (es) |
EA (1) | EA026431B1 (es) |
ES (1) | ES2607113T3 (es) |
HK (1) | HK1206332A1 (es) |
HR (1) | HRP20161690T1 (es) |
HU (1) | HUE030785T2 (es) |
IL (2) | IL234301A (es) |
LT (1) | LT2825542T (es) |
ME (1) | ME02660B (es) |
MX (1) | MX354820B (es) |
NZ (1) | NZ629189A (es) |
PL (1) | PL2825542T3 (es) |
PT (1) | PT2825542T (es) |
RS (1) | RS55532B1 (es) |
SG (1) | SG11201405323YA (es) |
SI (1) | SI2825542T1 (es) |
SM (1) | SMT201700009B (es) |
WO (1) | WO2013138568A1 (es) |
ZA (1) | ZA201406390B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6114815B2 (ja) * | 2012-03-16 | 2017-04-12 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 肝臓xレセプターモジュレーター |
WO2013138565A1 (en) * | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x receptor modulators |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
US20170231992A1 (en) * | 2014-06-19 | 2017-08-17 | Vitae Pharmaceuticals, Inc. | Compounds for use in treating acute coronary syndrome and related conditions |
ES2768685T3 (es) * | 2014-08-07 | 2020-06-23 | Vitae Pharmaceuticals Llc | Derivados de piperazina como moduladores de los receptores X del hígado |
EP3373935B1 (en) * | 2015-11-12 | 2021-09-01 | Merck Sharp & Dohme Corp. | Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use |
CN109069461A (zh) | 2016-01-11 | 2018-12-21 | 洛克菲勒大学 | 与髓源性抑制细胞相关的病症的治疗方法 |
BR112019001459A2 (pt) | 2016-07-27 | 2019-05-07 | Hartis-Pharma Sa | combinação, composição farmacêutica, e, método de prevenção e/ou de tratamento de uma doença ou de um distúrbio. |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
WO2019222265A1 (en) | 2018-05-15 | 2019-11-21 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
WO2020176846A2 (en) * | 2019-02-28 | 2020-09-03 | The Rockefeller University | Apoe genotyping in cancer prognostics and treatment |
EP3999055A1 (en) | 2019-07-15 | 2022-05-25 | Novartis AG | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4748247A (en) | 1986-10-21 | 1988-05-31 | American Home Products Corporation | 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists |
AU7165591A (en) | 1990-01-22 | 1991-08-05 | E.I. Du Pont De Nemours And Company | Herbicidal sulfonylureas |
EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
ES2236702T3 (es) | 1993-12-23 | 2005-07-16 | Eli Lilly And Company | Inhibidores de la proteina quinasa c. |
WO1996012721A1 (en) | 1994-10-20 | 1996-05-02 | American Home Products Corporation | Indole derivatives useful as serotonergic agents |
WO1998000401A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
EP0912175A4 (en) | 1996-06-28 | 1999-09-08 | Merck & Co Inc | FIBRINOGENIC RECEPTOR ANTAGONISTS |
AU709631B2 (en) | 1996-06-28 | 1999-09-02 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
US5854245A (en) | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US6177440B1 (en) | 1996-10-30 | 2001-01-23 | Eli Lilly And Company | Substituted tricyclics |
FR2761070B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
FR2761073B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
DE19802235A1 (de) | 1998-01-22 | 1999-07-29 | Bayer Ag | Mit tricyclischen Indolen substituierte Oxazolidinone |
ID23219A (id) | 1998-04-17 | 2000-03-30 | Lilly Co Eli | Trisiklik tersubstitusi |
MXPA01011173A (es) | 1999-05-06 | 2002-04-24 | Neurogen Corp | 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba. |
US7037916B2 (en) | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
IT1313593B1 (it) * | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo. |
WO2001030331A2 (en) | 1999-10-22 | 2001-05-03 | Eli Lilly And Company | Therapeutic compositions including protein kinase c inhibitors |
ATE387199T1 (de) | 2000-01-06 | 2008-03-15 | Merck Frosst Canada Ltd | Neue substanzen und verbindungen als protease- inhibitoren |
EP1325008B1 (en) | 2000-07-31 | 2005-10-05 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
CA2432122A1 (en) | 2000-12-20 | 2002-08-01 | Bristol-Myers Squibb Pharma Company | Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
FR2829766A1 (fr) | 2001-09-14 | 2003-03-21 | Lipha | Derives d'oxamates comportant un heterocycle azote diversement substitue |
IL162653A0 (en) | 2001-12-21 | 2005-11-20 | King Pharmaceuticals Reserch & | Tyrosyl derivatives and their use as p2x7 receptormodulators |
US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
DE10320780A1 (de) | 2003-05-09 | 2005-01-20 | Bayer Healthcare Ag | Heterocyclyl-substituierte Dihydrochinazoline |
JP4734119B2 (ja) | 2004-02-12 | 2011-07-27 | 田辺三菱製薬株式会社 | インダゾール化合物及びその医薬用途 |
EP1734952A1 (en) | 2004-04-08 | 2006-12-27 | Novartis AG | Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection |
RU2266906C1 (ru) | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
WO2005113526A2 (en) | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one |
MX2007006896A (es) * | 2004-12-15 | 2007-06-26 | Hoffmann La Roche | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
NZ555491A (en) | 2005-01-03 | 2010-01-29 | Univ Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
PL1904477T3 (pl) | 2005-07-14 | 2009-07-31 | Hoffmann La Roche | Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a |
EP1926724A1 (en) | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
JP4882127B2 (ja) * | 2005-11-16 | 2012-02-22 | 株式会社ジェイテクト | 位置調整式ステアリング装置 |
JP2007137810A (ja) * | 2005-11-17 | 2007-06-07 | Sankyo Co Ltd | インドール化合物を含有する医薬 |
WO2007065820A1 (en) | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
US7351706B2 (en) | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
FR2897061B1 (fr) | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US9096565B2 (en) | 2007-04-09 | 2015-08-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
CN101784541A (zh) | 2007-06-25 | 2010-07-21 | 纽罗根公司 | 哌嗪基氧代烷基四氢-β-咔啉及相关类似物 |
WO2009042092A1 (en) | 2007-09-25 | 2009-04-02 | Merck & Co., Inc. | 2-aryl or heteroaryl indole derivatives |
CN101456863B (zh) * | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
CN101952293A (zh) | 2007-12-21 | 2011-01-19 | 惠氏有限责任公司 | 吡唑并[1,5-a]嘧啶化合物 |
WO2009093747A1 (en) | 2008-01-22 | 2009-07-30 | Takeda Pharmaceutical Company Limited | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them |
US20090192147A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
US8207165B2 (en) | 2008-03-28 | 2012-06-26 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
TW201031665A (en) | 2009-02-04 | 2010-09-01 | Gruenenthal Gmbh | Substituted indole-compound |
CA2764622A1 (en) | 2009-06-08 | 2010-12-16 | Stefan Schunk | Substituted benzimidazoles, benzothiazoles and benzoxazoles |
WO2011005295A1 (en) | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
US20110065694A1 (en) | 2009-09-11 | 2011-03-17 | Milan Chytil | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof |
JP5643332B2 (ja) | 2009-12-07 | 2014-12-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物 |
US20130045203A1 (en) | 2010-03-02 | 2013-02-21 | Emory University | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
KR101302474B1 (ko) * | 2012-02-20 | 2013-09-02 | 주식회사 케이씨씨 | 내충격성 및 불연성이 우수한 진공단열재용 봉지부재 |
WO2013138565A1 (en) * | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x receptor modulators |
JP6114815B2 (ja) * | 2012-03-16 | 2017-04-12 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 肝臓xレセプターモジュレーター |
-
2013
- 2013-03-14 JP JP2015500603A patent/JP6114815B2/ja not_active Expired - Fee Related
- 2013-03-14 AU AU2013232069A patent/AU2013232069B2/en not_active Ceased
- 2013-03-14 SI SI201330426A patent/SI2825542T1/sl unknown
- 2013-03-14 CA CA2865639A patent/CA2865639C/en not_active Expired - Fee Related
- 2013-03-14 ES ES13712103.4T patent/ES2607113T3/es active Active
- 2013-03-14 RS RS20161114A patent/RS55532B1/sr unknown
- 2013-03-14 PL PL13712103T patent/PL2825542T3/pl unknown
- 2013-03-14 HU HUE13712103A patent/HUE030785T2/en unknown
- 2013-03-14 WO PCT/US2013/031250 patent/WO2013138568A1/en active Application Filing
- 2013-03-14 CN CN201380014301.3A patent/CN104203950B/zh not_active Expired - Fee Related
- 2013-03-14 EP EP13712103.4A patent/EP2825542B1/en active Active
- 2013-03-14 BR BR112014022780A patent/BR112014022780A8/pt not_active Application Discontinuation
- 2013-03-14 NZ NZ629189A patent/NZ629189A/en not_active IP Right Cessation
- 2013-03-14 DK DK13712103.4T patent/DK2825542T3/en active
- 2013-03-14 ME MEP-2016-289A patent/ME02660B/me unknown
- 2013-03-14 EA EA201491610A patent/EA026431B1/ru unknown
- 2013-03-14 PT PT137121034T patent/PT2825542T/pt unknown
- 2013-03-14 US US14/385,671 patent/US9073931B2/en active Active
- 2013-03-14 SG SG11201405323YA patent/SG11201405323YA/en unknown
- 2013-03-14 LT LTEP13712103.4T patent/LT2825542T/lt unknown
- 2013-03-14 MX MX2014011104A patent/MX354820B/es active IP Right Grant
- 2013-03-14 KR KR1020147028756A patent/KR102069913B1/ko active IP Right Grant
-
2014
- 2014-08-26 IL IL234301A patent/IL234301A/en active IP Right Grant
- 2014-08-29 ZA ZA201406390A patent/ZA201406390B/en unknown
-
2015
- 2015-05-26 US US14/721,262 patent/US9416135B2/en active Active
- 2015-07-16 HK HK15106802.8A patent/HK1206332A1/xx not_active IP Right Cessation
-
2016
- 2016-07-07 US US15/204,422 patent/US9707232B2/en active Active
- 2016-12-12 CY CY20161101280T patent/CY1118323T1/el unknown
- 2016-12-12 HR HRP20161690TT patent/HRP20161690T1/hr unknown
-
2017
- 2017-01-10 SM SM201700009T patent/SMT201700009B/it unknown
- 2017-03-14 JP JP2017048433A patent/JP2017128589A/ja active Pending
- 2017-04-25 IL IL251897A patent/IL251897A0/en unknown
- 2017-06-09 US US15/618,297 patent/US20180117041A1/en not_active Abandoned
-
2018
- 2018-09-14 JP JP2018172261A patent/JP2019006813A/ja active Pending
-
2019
- 2019-05-21 US US16/418,339 patent/US20200138812A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014011104A (es) | Moduladores del receptor x del higado. | |
MX2014011103A (es) | Moduladores del receptor x del higado. | |
PH12017501176A1 (en) | Pyruvate kinase activators for use therapy | |
PH12014502704B1 (en) | Compounds and compositions for modulating egfr activity | |
PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
GB201017345D0 (en) | Receptor antagonists | |
PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
TW201144301A (en) | Processes for preparing linezolid | |
PH12014502032A1 (en) | Treatment of brain cancer | |
MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
PH12017501816A1 (en) | Azabensimidazoles and their use as amp a receptor modulators | |
MX2012013855A (es) | Compuestos de oligobenzamida y su uso. | |
IN2014CN04050A (es) | ||
IN2014KN02993A (es) | ||
TN2014000136A1 (en) | Selective androgen receptor modulators | |
MY186475A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
EP2910246A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH ENOBLOCK AS AN ACTIVE SUBSTANCE | |
MX2015012043A (es) | Agonistas muscarinicos. | |
EA201391421A1 (ru) | Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана | |
MX351961B (es) | Analogos de diazonamida. | |
MX2015001134A (es) | Compuestos terapeuticos. | |
IN2013CH05395A (es) | ||
MY163393A (en) | Pharmaceutical formulations of telmisartan and process for preparing the same | |
UA105703C2 (uk) | 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |